Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Come from away: Best practices in mini-sabbaticals for the development of young investigators: a White Paper by the SEQUIN (mini-Sabbatical Evaluation and QUality ImprovemeNt) Group.

Pillinger MH, Lemon SC, Zand MS, Foster PJ Jr, Merchant JS, Kimberly R, Allison J, Cronstein BN, Galeano C, Holden-Wiltse J, Trayhan M, White RJ, Davin A, Saag KG.

J Clin Transl Sci. 2019 Feb;3(1):37-44. doi: 10.1017/cts.2019.369. Review.

2.

Measuring the Severity of Respiratory Illness in the First 2 Years of Life in Preterm and Term Infants.

Caserta MT, Yang H, Bandyopadhyay S, Qiu X, Gill SR, Java J, McDavid A, Falsey AR, Topham DJ, Holden-Wiltse J, Scheible K, Pryhuber G.

J Pediatr. 2019 Jul 31. pii: S0022-3476(19)30825-X. doi: 10.1016/j.jpeds.2019.06.061. [Epub ahead of print]

PMID:
31377041
3.

Aims, Study Design, and Enrollment Results From the Assessing Predictors of Infant Respiratory Syncytial Virus Effects and Severity Study.

Walsh EE, Mariani TJ, Chu C, Grier A, Gill SR, Qiu X, Wang L, Holden-Wiltse J, Corbett A, Thakar J, Benoodt L, McCall MN, Topham DJ, Falsey AR, Caserta MT.

JMIR Res Protoc. 2019 Jun 6;8(6):e12907. doi: 10.2196/12907.

4.

Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals.

Henry C, Zheng NY, Huang M, Cabanov A, Rojas KT, Kaur K, Andrews SF, Palm AE, Chen YQ, Li Y, Hoskova K, Utset HA, Vieira MC, Wrammert J, Ahmed R, Holden-Wiltse J, Topham DJ, Treanor JJ, Ertl HC, Schmader KE, Cobey S, Krammer F, Hensley SE, Greenberg H, He XS, Wilson PC.

Cell Host Microbe. 2019 Mar 13;25(3):357-366.e6. doi: 10.1016/j.chom.2019.01.002. Epub 2019 Feb 19.

PMID:
30795982
5.

Neonatal gut and respiratory microbiota: coordinated development through time and space.

Grier A, McDavid A, Wang B, Qiu X, Java J, Bandyopadhyay S, Yang H, Holden-Wiltse J, Kessler HA, Gill AL, Huyck H, Falsey AR, Topham DJ, Scheible KM, Caserta MT, Pryhuber GS, Gill SR.

Microbiome. 2018 Oct 26;6(1):193. doi: 10.1186/s40168-018-0566-5.

6.

Dissociation, cellular isolation, and initial molecular characterization of neonatal and pediatric human lung tissues.

Bandyopadhyay G, Huyck HL, Misra RS, Bhattacharya S, Wang Q, Mereness J, Lillis J, Myers JR, Ashton J, Bushnell T, Cochran M, Holden-Wiltse J, Katzman P, Deutsch G, Whitsett JA, Xu Y, Mariani TJ, Pryhuber GS.

Am J Physiol Lung Cell Mol Physiol. 2018 Oct 1;315(4):L576-L583. doi: 10.1152/ajplung.00041.2018. Epub 2018 Jul 5.

PMID:
29975103
7.

T-Cell Responses in Adults During Natural Respiratory Syncytial Virus Infection.

Roumanes D, Falsey AR, Quataert S, Secor-Socha S, Lee FE, Yang H, Bandyopadhyay S, Holden-Wiltse J, Topham DJ, Walsh EE.

J Infect Dis. 2018 Jul 2;218(3):418-428. doi: 10.1093/infdis/jiy016.

8.

Effect of prior vaccination on carriage rates of Streptococcus pneumoniae in older adults: A longitudinal surveillance study.

Branche AR, Yang H, Java J, Holden-Wiltse J, Topham DJ, Peasley M, Frost MR, Nahm MH, Falsey AR.

Vaccine. 2018 Jul 5;36(29):4304-4310. doi: 10.1016/j.vaccine.2018.05.107. Epub 2018 Jun 2.

PMID:
29871816
9.

Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection.

Walsh EE, Wang L, Falsey AR, Qiu X, Corbett A, Holden-Wiltse J, Mariani TJ, Topham DJ, Caserta MT.

J Infect Dis. 2018 Jun 20;218(2):208-217. doi: 10.1093/infdis/jiy106.

10.

T cell developmental arrest in former premature infants increases risk of respiratory morbidity later in infancy.

Scheible KM, Emo J, Laniewski N, Baran AM, Peterson DR, Holden-Wiltse J, Bandyopadhyay S, Straw AG, Huyck H, Ashton JM, Tripi KS, Arul K, Werner E, Scalise T, Maffett D, Caserta M, Ryan RM, Reynolds AM, Ren CL, Topham DJ, Mariani TJ, Pryhuber GS.

JCI Insight. 2018 Feb 22;3(4). pii: 96724. doi: 10.1172/jci.insight.96724. eCollection 2018 Feb 22.

11.

Impact of prematurity and nutrition on the developing gut microbiome and preterm infant growth.

Grier A, Qiu X, Bandyopadhyay S, Holden-Wiltse J, Kessler HA, Gill AL, Hamilton B, Huyck H, Misra S, Mariani TJ, Ryan RM, Scholer L, Scheible KM, Lee YH, Caserta MT, Pryhuber GS, Gill SR.

Microbiome. 2017 Dec 11;5(1):158. doi: 10.1186/s40168-017-0377-0.

12.

Association of Dynamic Changes in the CD4 T-Cell Transcriptome With Disease Severity During Primary Respiratory Syncytial Virus Infection in Young Infants.

Mariani TJ, Qiu X, Chu C, Wang L, Thakar J, Holden-Wiltse J, Corbett A, Topham DJ, Falsey AR, Caserta MT, Walsh EE.

J Infect Dis. 2017 Nov 15;216(8):1027-1037. doi: 10.1093/infdis/jix400.

13.

Transcriptomic Biomarkers to Discriminate Bacterial from Nonbacterial Infection in Adults Hospitalized with Respiratory Illness.

Bhattacharya S, Rosenberg AF, Peterson DR, Grzesik K, Baran AM, Ashton JM, Gill SR, Corbett AM, Holden-Wiltse J, Topham DJ, Walsh EE, Mariani TJ, Falsey AR.

Sci Rep. 2017 Jul 26;7(1):6548. doi: 10.1038/s41598-017-06738-3.

14.

Maximum Likelihood Estimation of Titer via a Power Family of Four-Parameter Logistic Model.

Yang H, Holden-Wiltse J, Topham DJ, Treanor J.

J Biopharm Stat. 2018;28(3):492-500. doi: 10.1080/10543406.2017.1333996. Epub 2017 Sep 5.

15.

Viral Respiratory Infections in Preterm Infants during and after Hospitalization.

Caserta MT, Yang H, Gill SR, Holden-Wiltse J, Pryhuber G.

J Pediatr. 2017 Mar;182:53-58.e3. doi: 10.1016/j.jpeds.2016.11.077. Epub 2016 Dec 30.

16.

Development of a Global Respiratory Severity Score for Respiratory Syncytial Virus Infection in Infants.

Caserta MT, Qiu X, Tesini B, Wang L, Murphy A, Corbett A, Topham DJ, Falsey AR, Holden-Wiltse J, Walsh EE.

J Infect Dis. 2017 Mar 1;215(5):750-756. doi: 10.1093/infdis/jiw624. Erratum in: J Infect Dis. 2017 Sep 15;216(6):786.

17.

The Healthy Infant Nasal Transcriptome: A Benchmark Study.

Chu CY, Qiu X, Wang L, Bhattacharya S, Lofthus G, Corbett A, Holden-Wiltse J, Grier A, Tesini B, Gill SR, Falsey AR, Caserta MT, Walsh EE, Mariani TJ.

Sci Rep. 2016 Sep 23;6:33994. doi: 10.1038/srep33994.

18.

Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.

DeDiego ML, Anderson CS, Yang H, Holden-Wiltse J, Fitzgerald T, Treanor JJ, Topham DJ.

Immunology. 2016 Jun;148(2):160-73. doi: 10.1111/imm.12594. Epub 2016 Mar 30.

19.

Developmentally determined reduction in CD31 during gestation is associated with CD8+ T cell effector differentiation in preterm infants.

Scheible KM, Emo J, Yang H, Holden-Wiltse J, Straw A, Huyck H, Misra S, Topham DJ, Ryan RM, Reynolds AM, Mariani TJ, Pryhuber GS.

Clin Immunol. 2015 Dec;161(2):65-74. doi: 10.1016/j.clim.2015.07.003. Epub 2015 Jul 29.

20.

An improved method for estimating antibody titers in microneutralization assay using green fluorescent protein.

Yang H, Baker SF, González ME, Topham DJ, Martínez-Sobrido L, Zand M, Holden-Wiltse J, Wu H.

J Biopharm Stat. 2016;26(3):409-20. doi: 10.1080/10543406.2015.1052475. Epub 2015 May 26.

21.

Modeling the dynamics and migratory pathways of virus-specific antibody-secreting cell populations in primary influenza infection.

Miao H, Sangster MY, Livingstone AM, Hilchey SP, Zhang L, Topham DJ, Mosmann TR, Holden-Wiltse J, Perelson AS, Wu H, Zand MS.

PLoS One. 2014 Aug 29;9(8):e104781. doi: 10.1371/journal.pone.0104781. eCollection 2014.

22.

A strategy to model nonmonotonic dose-response curve and estimate IC50.

Zhang H, Holden-Wiltse J, Wang J, Liang H.

PLoS One. 2013 Aug 1;8(8):e69301. doi: 10.1371/journal.pone.0069301. Print 2013.

23.

High-resolution temporal response patterns to influenza vaccine reveal a distinct human plasma cell gene signature.

Henn AD, Wu S, Qiu X, Ruda M, Stover M, Yang H, Liu Z, Welle SL, Holden-Wiltse J, Wu H, Zand MS.

Sci Rep. 2013;3:2327. doi: 10.1038/srep02327.

24.

Statistical estimation & inference of cell counts from ELISPOT limiting dilution assays.

Yang H, Topham DJ, Holden-Wiltse J, Wu H.

J Biopharm Stat. 2013;23(4):921-36. doi: 10.1080/10543406.2013.790645.

25.

Modeling of influenza-specific CD8+ T cells during the primary response indicates that the spleen is a major source of effectors.

Wu H, Kumar A, Miao H, Holden-Wiltse J, Mosmann TR, Livingstone AM, Belz GT, Perelson AS, Zand MS, Topham DJ.

J Immunol. 2011 Nov 1;187(9):4474-82. doi: 10.4049/jimmunol.1101443. Epub 2011 Sep 23.

26.
27.

Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.

Dykes C, Wu H, Sims M, Holden-Wiltse J, Demeter LM.

J Clin Microbiol. 2010 Nov;48(11):4035-43. doi: 10.1128/JCM.00605-10. Epub 2010 Sep 8.

28.

Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus.

Miao H, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR, Perelson AS, Wu H, Topham DJ.

J Virol. 2010 Jul;84(13):6687-98. doi: 10.1128/JVI.00266-10. Epub 2010 Apr 21.

29.

B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant.

Baer J, Santiago F, Yang H, Wu H, Holden-Wiltse J, Treanor J, Topham DJ.

Vaccine. 2010 Jan 22;28(4):907-15. doi: 10.1016/j.vaccine.2009.11.002. Epub 2009 Nov 21.

30.

Simulation and prediction of the adaptive immune response to influenza A virus infection.

Lee HY, Topham DJ, Park SY, Hollenbaugh J, Treanor J, Mosmann TR, Jin X, Ward BM, Miao H, Holden-Wiltse J, Perelson AS, Zand M, Wu H.

J Virol. 2009 Jul;83(14):7151-65. doi: 10.1128/JVI.00098-09. Epub 2009 May 13.

31.

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.

Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M.

JAMA. 2007 Apr 11;297(14):1577-82.

PMID:
17426277
32.

Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS.

Jacobson JM, Hafner R, Remington J, Farthing C, Holden-Wiltse J, Bosler EM, Harris C, Jayaweera DT, Roque C, Luft BJ; ACTG 156 Study Team.

AIDS. 2001 Mar 30;15(5):583-9.

PMID:
11316995
33.

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC.

Antimicrob Agents Chemother. 2000 Mar;44(3):794-7.

34.

ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.

Para MF, Meehan P, Holden-Wiltse J, Fischl M, Morse G, Shafer R, Demeter LM, Wood K, Nevin T, Virani-Ketter N, Freimuth WW.

Antimicrob Agents Chemother. 1999 Jun;43(6):1373-8.

35.

Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258.

Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT.

Ann Intern Med. 1999 Mar 16;130(6):510-4.

PMID:
10075619
36.

Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.

Demeter LM, Meehan PM, Morse G, Fischl MA, Para M, Powderly W, Leedom J, Holden-Wiltse J, Greisberger C, Wood K, Timpone J Jr, Wathen LK, Nevin T, Resnick L, Batts DH, Reichman RC.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):135-44.

PMID:
9768622
37.

Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team.

Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi JP, Shriver SL, Suckow CW, Gill PS.

J Clin Oncol. 1998 Apr;16(4):1444-9.

PMID:
9552050
38.

Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.

Fischl MA, Richman DD, Saag M, Meng TC, Squires KE, Holden-Wiltse J, Meehan PM.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 1;16(4):247-53.

PMID:
9402071
39.

Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151.

Fischl MA, Richman DD, Flexner C, Para MF, Haubrich R, Karim A, Yeramian P, Holden-Wiltse J, Meehan PM.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 May 1;15(1):28-34.

PMID:
9215651
40.

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.

Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith BP, Clax PA, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y, Crumpacker CS.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):235-46.

PMID:
8898668
41.

Taste responses and food preferences in obese women: effects of weight cycling.

Drewnowski A, Holden-Wiltse J.

Int J Obes Relat Metab Disord. 1992 Sep;16(9):639-48.

PMID:
1328087
42.

Food preferences in human obesity: carbohydrates versus fats.

Drewnowski A, Kurth C, Holden-Wiltse J, Saari J.

Appetite. 1992 Jun;18(3):207-21.

Supplemental Content

Loading ...
Support Center